TY - T1的美国国立卫生研究院注册使用的翼展为symptomatic70 - 99%颅内动脉狭窄支架JF -神经学乔-神经病学SP - 1518 LP - 1524——10.1212/01. wnl.0000306308.08229。首页a3六世- 70 - 17 AU - o . o . Zaidat AU - r . Klucznik AU - m·j·亚历山大盟- j . Chaloupka AU - h . Lutsep AU - s Barnwell AU - m . Mawad AU - b . Lane AU - m·j·林恩AU - m . Chimowitz A2, Y1 - 2008/04/22 UR - //www.ez-admanager.com/co首页ntent/70/17/1518.abstract N2 -背景:Warfarin-Aspirin症状颅内疾病(WASID)试验表明,患者症状性颅内动脉狭窄70%到99%的风险特别高侧中风药物治疗:1年18% (95% CI = 3%到24%)。翼展颅内支架是另一种治疗选择,但支架的技术成功有有限的数据和结果的70%到99%狭窄患者治疗的翼展支架。方法:患者连续十六个医疗中心登记翼展支架在这个注册表在2005年11月和2006年10月之间。支架上的数据表明,狭窄的严重程度,技术成功(支架放置在目标病变& lt; 50%残余狭窄),随访造影,结果被收集。结果:共有129例症状性颅内狭窄为70%至99%。技术的成功率是96.7%。平均前和post-stent狭窄分别为82%和20%。任何频率的中风,脑内出血,30天内死亡或身体的同侧的中风超出30天在6个月时14.0% (95% CI = 8.7%到22.1%)。再狭窄的频率≥50%随访造影是13/52 (25%)。 Conclusion: The use of a Wingspan stent in patients with severe intracranial stenosis is relatively safe with high rate of technical success with moderately high rate of restenosis. Comparison of the event rates in high-risk patients in Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) vs this registry do not rule out either that stenting could be associated with a substantial relative risk reduction (e.g., 50%) or has no advantage compared with medical therapy. A randomized trial comparing stenting with medical therapy is needed. GLOSSARY: FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICH = intracerebral hemorrhage; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease. ER -